Reporter brief
Senolytic drug reduced bacterial burden in vitro model of chronic intracellular infection
What happened
An in vitro study examined how Mycobacterium abscessus infection induces senescence in alveolar macrophages through DNA damage signalling, which then spreads to neighboring cells via paracrine SASP secretion. Treatment with the senolytic drug Navitoclax selectively eliminated senescent cells and reduced bacterial burden to levels similar to antibiotic treatment.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
In vitro; Mixed.
Alveolar macrophages infected with Mycobacterium abscessus and neighboring uninfected cells
- Design
- In vitro
- Sample
- —
- Journal
- Nature Communications
- Published
- Aug 18, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.